View Biomed Group's Articles BY TICKER:
Vital Therapies Stands To Benefit From The High Unmet Need In Treating ALF Patients
- Vital's ELAD system may become a future therapy for the treatment of patients suffering from acute liver failure.
- Vital shares are attractive based on a robust orphan market opportunity in ALF, where no effective non-transplants are available.
- Positive Phase III data in H1/15 is expected to boost shares.
EnteroMedics: Recent Sell-Off In Biotech Creates A Great Entry Opportunity
- ETRM is very attractive after the recent pullback in the biotechnology sector and provides an opportunity.
- Important near-term catalysts should drive ETRM shares higher.
- Obesity represents a potential of more than $1 Billion market opportunity for the company.
GlycoMimetics: A Promising Sickle Cell Disease Play
- GlycoMimetics’ GMI-1070 is a first-in-class pan-selectin inhibitor that could shorten sickle cell disease vaso-occlusive crisis, and has the potential for more than 1 billion peak sales.
- Strong Phase 2 GMI-1070 data showed consistent improvements in the duration of crisis, use of opiods, and other clinical metrics, which bodes well for Phase 3 chance of success.
- While early, GlycoMimetics’ GMI-1271 for the treatment of AML could drive GLYC shares meaningfully higher.
- Fibrocell Science: An Attractive Healthcare Investment
- Chimerix: A Significant Player In The Antiviral Therapeutics Market
- Aratana Therapeutics: A Growing Player Within The Emerging Pet Therapeutics Market
- Five Prime: A Growing Oncology And Inflammatory Player With A Promising Pipeline
- Heat Biologics: An Undervalued Cancer Vaccine Play That Leaves Considerable Room For Upside
- Alphatec Holdings: An Undervalued Spine Player With A Potential Growth Opportunity
- NanoString: An Exciting Small Cap Story With A Strong Growth Outlook
- Verastem: An Attractive Long-Term Investment In The Cancer Stem Cell Space
- Alcobra: An Interesting Investment Opportunity In The Healthcare Space
- Insys Therapeutics: A Profitable Pharmaceutical Company With Great Potential Growth
- Galena Biopharma: Promising Pipeline Points To A Bright Future
- KaloBios: An Undervalued Pharmaceutical Company With Remarkable Pipeline
- MEI Pharma: The Good And The Bad
- Amicus Therapeutics: The Good And The Bad
- Onyx Pharmaceuticals: Kyprolis Is The Key Driver Of Future Growth
- OncoGenex: SYNERGY Trial Is The Major Catalyst In Sight
- Medivation: Early Launch Of Xtandi Appears Solid
- Dynavax Technologies: Key Issues To Consider
- Omeros Corporation's Stock Has Potential To Double This Year
- Amgen: A Long-Term Growth Story
- FISSION Study Should Support Regulatory Approval For Gilead's Hepatitis C Drug